Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping. The post BNGO Stock: What Is Driving Bionano Genomics Higher Today?

BNGO Stock: What Is Driving Bionano Genomics Higher Today?

SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced the publication of the largest clinical research study to date evaluating optical genome mapping (OGM) for facioscapulohumeral muscular dystrophy (FSHD), which concluded that OGM can be performed more quickly, accurately, and reproducibly than the current gold standard method of Southern blot analysis. This study, now available online before print in The Journal of Molecular Diagnostics, describes how OGM can be adopted as an alternative to Southern blot analysis for the identification of chromosomal abnormalities associated with FSHD, a neuromuscular disorder resulting in progressive weakness and atrophy of muscles.

Largest Clinical Research Study to Date Evaluating Optical Genome Mapping for Analysis of Facioscapulohumeral Muscular Dystrophy Showed Concordance with Southern Blot and Reduced Turnaround Time by 50% as Compared to the Traditional Workflow

Canopy Growth

Skillz

Viatris

Analysts' loftiest price targets portend significant upside for these widely owned (and followed) stocks.

5 Ultra-Popular Stocks With 120% to 190% Upside, According to Wall Street

C3.ai

Pubmatic

All three of these tech names, driven by very strong positive catalysts, should rally over the longer term, leading to high profits for investors. The post 3 Top Tech Stocks to Buy on Weakness appeared first on InvestorPlace.

3 Top Tech Stocks to Buy on Weakness

BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system. The post Bionano Genomics Remains Promising With Global Product Adoption appeared first on InvestorPlace.

Bionano Genomics Remains Promising With Global Product Adoption

Blink Charging

Vaxart

These under-the-radar companies are expected to deliver jaw-dropping revenue growth over the next four years.

4 Small-Cap Growth Stocks Expected to Increase Sales 707% to 9,406% by 2024

SAN DIEGO and SHANGHAI, China, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that NuProbe Global, a global molecular diagnostics company based in Shanghai, China and Houston, Texas, has adopted Bionano's Saphyr system for optical genome mapping (OGM) to integrate their Quantitative Amplicon Sequencing (QASeq) and Blocker Displacement Amplification (BDA) technologies for research and product development in the fields of reproductive health and oncology liquid biopsies.

NuProbe Global Adopts Bionano's Saphyr® System to Develop Products in Reproductive Health and Oncology Applications

With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable. The post The Price Is Right for BioNano Genomics Given Saphyr's Potential appeared first on InvestorPlace.

The Price Is Right for BioNano Genomics Given Saphyr's Potential

As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock. The post Bionano Stock Will Soar as the Company's Diagnostic System Catches On appeared first on InvestorPlace.

Bionano Stock Will Soar as the Company's Diagnostic System Catches On

Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors. The post Faster and Better Clinical Outcomes Make the Case for Bionano Genomics appeared first on InvestorPlace.

Faster and Better Clinical Outcomes Make the Case for Bionano Genomics

Bionano Genomics' (BNGO) CEO Erik Holmlin on Q2 2021 Results - Earnings Call Transcript

SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today reported financial results and business achievements for the second quarter ended June 30, 2021 and highlighted recent corporate updates.

Bionano Genomics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Progress

Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals.

Bionano's Technology Is Interesting, But Its Earnings Are Uninspiring

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 4, 2021 at 4:30 p.m. Eastern Time to report financial results for the second quarter ended June 30, 2021 and to highlight recent corporate progress.

Bionano Genomics to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 4, 2021

In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $5.87, marking a -1.68% move from the previous day.

Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock.

Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics

With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip. The post You'd Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush appeared first on InvestorPlace.

You'd Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush

Invitae

OPKO Health

The market's pessimism about these diagnostics stocks appeared unrelated to company-specific news.

Why Bionano Genomics, Invitae, and Opko Health Stocks Sank This Week

Arrival Group

BlackBerry

Wish

Not all meme stocks are overvalued. These four meme stocks are good buys, as they're poised to deliver big profits for investors.

4 Highly Promising Meme Stocks to Buy Now

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two peer-reviewed studies from world renowned scientists and clinicians from prestigious institutions in Europe including Radboud University Medical Center, Cochin Hospital in Paris, Hospices Civils in Lyon and the University Hospital of Clermont-Ferrand were published back-to-back in the American Journal of Human Genetics. One study analyzed the genomes of patients with inherited genetic disease and one study those of hematological malignancies. These seminal papers outline the utility of optical genome mapping (OGM) as a superior alternative to traditional methods for structural variant (SV) analysis. The results showed OGM was 100% concordant with findings from fluorescent in-situ hybridization (FISH), karyotype, and CNV-microarray when these traditional methods identified one or more pathogenic variants in samples from study subjects. Additionally, the higher resolution of OGM for all types of variants relative to traditional cytogenomics techniques allowed for a more precise characterization of breakpoints and the identification of genes they affect, the detection of smaller cancer-associated events that usually escape detection by traditional means, and the discovery of additional complexity of rearrangements. These publications will appear in the August print issue and are available online today at http://www.cell.com/ajhg

Bionano Genomics Announces Back-to-Back Publications in the American Journal of Human Genetics that Compare Optical Genome Mapping to Traditional Methods for Structural Variant Analysis in Inherited Genetic Disease and Hematological Malignancies

DraftKings

Kinross Gold

Snowflake

Analysts for these sought-after companies foresee upside ranging from 105% to 144% over the next year.

Can These 5 Popular Stocks Double in 12 Months? Wall Street Thinks So

SAN DIEGO, July 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Chief Medical Officer Dr. Alka Chaubey and current President of the Cancer Genomics Consortium Dr. Yassmine Akkari will present at the 6th Annual International Conference of the Board of Genetic Counseling India to be held virtually from July 2nd-4th 2021. Dr. Chaubey has been recognized to present as an invited speaker and will discuss how optical genome mapping (OGM) is enabling a revolution in cytogenetics during a session titled “Genetic Counseling in the Omics Era” on Saturday July 3rd at 9:25 am IST. Dr. Akkari will present her results using OGM for the genome analysis of Acute Myelogenous Leukemia (AML), and discuss how genetic counselors can introduce OGM to patients on July 3rd at 4:10 pm IST. Bionano Genomics is a Diamond Sponsor of the conference.

Bionano Genomics' Chief Medical Officer Dr. Alka Chaubey and Cancer Genomics Consortium President Dr. Yassmine Akkari to Present on Optical Genome Mapping (OGM) at the 2021 International Conference of the Board of Genetic Counseling India

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference being held July 13-14, 2021. Erik Holmlin, PhD, Bionano's Chief Executive Officer, will present a company overview on July 13, 2021 at 4:30pm EDT.

Bionano Genomics to Present at the 2021 Ladenburg Thalmann Healthcare Conference

Anavex Life Sciences

GT Biopharma Inc

MannKind

Mogo

Qumu Corp.

Comscore Inc.

Current & Former Penny Stocks With High Marks From Analysts Right Now. The post 7 Hot Penny Stocks Analysts Like To Watch In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Bionano Genomics Stock (BNGO)